Leading Global CRO Selects iCardiac as Preferred Vendor Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services Top Five International Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac Leading Biotechnology Company Awards Phase III Cardiac Safety Study to iCardiac Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac iCardiac’s COMPAS Analytics Used in Recent New Drug Approval iCardiac Expands Sales and Marketing Team iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies iCardiac Selected by Top 10 Pharmaceutical Company iCardiac Selected for Multiple Cardiac Safety Studies iCardiac’s Highly Automated QT^sm Technology Cross-Validated Against Results from Five Leading ECG Core Laboratories Avoiding False Positives Key Priority in Cardiac Safety Studies iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company iCardiac Reports Significant Revenue Growth and Profitability iCardiac's Highly Automated QT^sm Technology Now Validated in Over 10 Clinical QT Studies iCardiac's COMPAS Technology Validated in Peer Reviewed Publication Co-Authored by FDA and University of Rochester iCardiac Applies Automated Approach to Thorough QT Study for a Leading Pharmaceutical Company iCardiac Completes Industry’s Largest Validation Study of Highly Automated QT Analysis iCardiac Joins Prominent Health-Care Policy Organization Former Pfizer Research Fellow Assumes Key Role at iCardiac Technologies iCardiac Announces Development of Next Generation COMPAS 3.0 Software Platform iCardiac Technologies Raises Funds To Develop Personalized Approach to Cardiac Safety Network Formed to Tackle Cardiac Safety Challenge iCardiac Appoints Chief Financial Officer iCardiac Appoints Three New Members to the Board of Directors iCardiac Technologies Enters into Cardiac Safety Alliance with Pfizer iCardiac Wins Technology Innovation Of The Year Award iCardiac Technologies Completes Oversubscribed Series A Round iCardiac Moves Into New Corporate Headquarters Trillium Group And New York State Comptroller Announce Multi-Million Dollar Investment in iCardiac Venture Capital Forum Selects Company for Best Presentation Award iCardiac, URMC Ink Exclusive Agreement for Breakthrough Medical Technology iCardiac Technologies Appoints Alex Zapesochny as President and COO

 

Drug Safety Executive Council – Avoiding False Cardiac Signals in Early Drug Development UR gets $2.3M for heart study
Chief tech officer at iCardiac Technologies will lead effort Feeling the Beat
Sasha Latypova and Mikael Totterman at iCardiac look at de-risking drug candidates in early clinical development Drug Safety Executive Council – De-Risking Drug Candidates in Early Clinical Development Intelligent ECG: Three years after the E14 guidance, Alexandra Latypova at iCardiac Technologies, Inc investigates new cardiac safety assessment challenges and potential solutions in European Pharmaceutical Contractor Spring 2009 Issue Drug Discovery & Development: What Lies Ahead? Drug Research Predictions - iCardiac Technologies
by Drug Discovery & Development In a Heartbeat as seen in Samedan LTD Spring 2008 Screen Door is Wide Open as seen in R&D Directions April 2008 Universities and the local economy Strong pulse at iCardiac in Brighton Integrated approach to TQT CenterWatch Profile on Cardiac Safety Network News 13 WHAM: "UR Spins Off Support for High Tech Business" Engineering K12 Center: "Ending Pharmaceutical Heartbreak" Rochester Medicine: “Leadership in Technology Commercialization” Health Business Blog: "Interview with Chairman and CEO of iCardiac, Mike Totterman" Rnews: "Entrepreneurs Make Their Pitch" Start-Up Magazine (In Vivo Publication): "iCardiac Technologies Inc. - A Better Rhythm for Drug Development" R&D Directions: "A Cardiac Pact"